Surgical management of extra-regional lymph node metastasis in colorectal cancer

Mahdi H. Albandar, Min Soo Cho, Sung Uk Bae, Namkyu Kim

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

ABSTRACT: One of the major problems in rectal cancer surgery is local recurrence, found in an average of 21% to 46% cases in 1990. However, the advent of chemo-radiotherapy (CRT) and total mesorectal excision (TME) improve local control and enhances survival rates in colorectal cancer (CRC). Regional lymph node involvement is determined to be an independent prognostic factor in local recurrence; however, extra-regional lymph node (ERLN) metastasis has a higher recurrence rate (up to 58.1%). Lack of supportive data in management of ERLN metastasis in CRC has added further strain and challenges to structure a unique treatment strategy. ERLN refers to extra-mesenteric involvement either in the para-aortic lymph node (PALN) or the lateral pelvic lymph node (LPLN). Treatment of ERLN metastasis is challenging because of the shortage of the resources. Here, we will outline and summarize approaches and management of ERLN metastasis. We also aim to clarify the role of surgical intervention in CRC

Original languageEnglish
Pages (from-to)503-513
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume16
Issue number5
DOIs
Publication statusPublished - 2016 May 3

Fingerprint

Colorectal Neoplasms
Lymph Nodes
Neoplasm Metastasis
Recurrence
Rectal Neoplasms
Radiotherapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

Albandar, Mahdi H. ; Cho, Min Soo ; Bae, Sung Uk ; Kim, Namkyu. / Surgical management of extra-regional lymph node metastasis in colorectal cancer. In: Expert Review of Anticancer Therapy. 2016 ; Vol. 16, No. 5. pp. 503-513.
@article{441f8f2215214b628bd6fffb3f229028,
title = "Surgical management of extra-regional lymph node metastasis in colorectal cancer",
abstract = "ABSTRACT: One of the major problems in rectal cancer surgery is local recurrence, found in an average of 21{\%} to 46{\%} cases in 1990. However, the advent of chemo-radiotherapy (CRT) and total mesorectal excision (TME) improve local control and enhances survival rates in colorectal cancer (CRC). Regional lymph node involvement is determined to be an independent prognostic factor in local recurrence; however, extra-regional lymph node (ERLN) metastasis has a higher recurrence rate (up to 58.1{\%}). Lack of supportive data in management of ERLN metastasis in CRC has added further strain and challenges to structure a unique treatment strategy. ERLN refers to extra-mesenteric involvement either in the para-aortic lymph node (PALN) or the lateral pelvic lymph node (LPLN). Treatment of ERLN metastasis is challenging because of the shortage of the resources. Here, we will outline and summarize approaches and management of ERLN metastasis. We also aim to clarify the role of surgical intervention in CRC",
author = "Albandar, {Mahdi H.} and Cho, {Min Soo} and Bae, {Sung Uk} and Namkyu Kim",
year = "2016",
month = "5",
day = "3",
doi = "10.1586/14737140.2016.1162718",
language = "English",
volume = "16",
pages = "503--513",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "5",

}

Surgical management of extra-regional lymph node metastasis in colorectal cancer. / Albandar, Mahdi H.; Cho, Min Soo; Bae, Sung Uk; Kim, Namkyu.

In: Expert Review of Anticancer Therapy, Vol. 16, No. 5, 03.05.2016, p. 503-513.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Surgical management of extra-regional lymph node metastasis in colorectal cancer

AU - Albandar, Mahdi H.

AU - Cho, Min Soo

AU - Bae, Sung Uk

AU - Kim, Namkyu

PY - 2016/5/3

Y1 - 2016/5/3

N2 - ABSTRACT: One of the major problems in rectal cancer surgery is local recurrence, found in an average of 21% to 46% cases in 1990. However, the advent of chemo-radiotherapy (CRT) and total mesorectal excision (TME) improve local control and enhances survival rates in colorectal cancer (CRC). Regional lymph node involvement is determined to be an independent prognostic factor in local recurrence; however, extra-regional lymph node (ERLN) metastasis has a higher recurrence rate (up to 58.1%). Lack of supportive data in management of ERLN metastasis in CRC has added further strain and challenges to structure a unique treatment strategy. ERLN refers to extra-mesenteric involvement either in the para-aortic lymph node (PALN) or the lateral pelvic lymph node (LPLN). Treatment of ERLN metastasis is challenging because of the shortage of the resources. Here, we will outline and summarize approaches and management of ERLN metastasis. We also aim to clarify the role of surgical intervention in CRC

AB - ABSTRACT: One of the major problems in rectal cancer surgery is local recurrence, found in an average of 21% to 46% cases in 1990. However, the advent of chemo-radiotherapy (CRT) and total mesorectal excision (TME) improve local control and enhances survival rates in colorectal cancer (CRC). Regional lymph node involvement is determined to be an independent prognostic factor in local recurrence; however, extra-regional lymph node (ERLN) metastasis has a higher recurrence rate (up to 58.1%). Lack of supportive data in management of ERLN metastasis in CRC has added further strain and challenges to structure a unique treatment strategy. ERLN refers to extra-mesenteric involvement either in the para-aortic lymph node (PALN) or the lateral pelvic lymph node (LPLN). Treatment of ERLN metastasis is challenging because of the shortage of the resources. Here, we will outline and summarize approaches and management of ERLN metastasis. We also aim to clarify the role of surgical intervention in CRC

UR - http://www.scopus.com/inward/record.url?scp=84964058548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964058548&partnerID=8YFLogxK

U2 - 10.1586/14737140.2016.1162718

DO - 10.1586/14737140.2016.1162718

M3 - Review article

VL - 16

SP - 503

EP - 513

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 5

ER -